Altogen Labs extensive biotechnology and pharmacology research services include the following:
- PRE-CLINICAL RESEARCH SERVICES
- Pharmacology and toxicology testing: IC50 for Tumor Cell Lines
- Xenograft Animal Service: Immunocompromised NOD/SCID Mice
- Therapeutic RNAi development: targeted siRNA, qPCR assays
- Liposome Encapsulation services: siRNA, miRNA, DNA, proteins
- ELISA and Cell-Based Assay Development (Cell Cycle, Viability)
- Apoptosis Assay: Caspase-3 and Caspase-7 Cell Line Screen
- RNAi Consulting Services: technology delevopment & evaluation
- GENERATION OF STABLE CELL LINES
- CELL BANKING
- RNA INTERFERENCE (RNAi) SERVICES
- In vivo siRNA delivery and tissue-targeting
- siRNA Transfection and RNAi Cell-based Library Screening
- Generation of Tet-inducible RNAi gene knockdown cell lines
- RNAi screen pathway analysis: siRNA and microRNA library
- RNAi manufacturing and CRO services
- PCR Cloning: shRNA-encoding vector construction
- In Vivo Stable siRNA and microRNA - Chemical modification
- Quantitation sh/siRNA-induced knockdown by qRT-PCR and WB
- Reporter gene assays and Stable RNAi cell line development
- Genome-wide siRNA and microRNA high-throughput screens
- Stable RNAi Cell Line Generation: Stable Gene Knockdown
- siRNA liposome encapsulation service
- Transient (siRNA) and stable (shRNA) transfection services
- BIOLOGY LABORATORY CRO SERVICES
- BIOREMEDIATION
- BACTERIA ID 16S SEQUENCING
RNAi Consulting Services: technology delevopment & evaluation
Altogen Labs provides RNA Interference (RNAi) consulting services to biopharmaceutical companies and research organizations worldwide. We help clients to move most advanced RNAi research from idea to clinics.
Our clients include RNAi industry leaders and research institutions. For each client we help on every step of the proces: laboratory technology evaluation, in vitro and in vivo testing, delivery and stability studies, IND submission, RNAi product development strategy, marketing, and delivery of solutions that ensure value and tangible results.
We are focused on biotechnology RNAi therapeutics commercialization via partnering with venture capital and major biotech and pharmaceutical companies. Our product development strategy focuses on therapeutic applications of RNA-based biomolecules. As the market for RNAi oligonucleotide-based medicines continues to grow, we help our clients to develop and introduce novel RNAi products to the market.
Our consultants assist clients in many ways, including pre-clinical invitro and invivo technology evaluation, gene silencing therapeutic effect testing, technology characterization, biomedical RNAi grant writing and reports preparation, marketing, developing strategies for filing FDA applications.
see also: Pharmacology and toxicology testing: IC50 for Tumor Cell Lines | Xenograft Animal Service: Immunocompromised NOD/SCID Mice | Therapeutic RNAi development: targeted siRNA, qPCR assays | Liposome Encapsulation services: siRNA, miRNA, DNA, proteins | ELISA and Cell-Based Assay Development (Cell Cycle, Viability) | Apoptosis Assay: Caspase-3 and Caspase-7 Cell Line Screen | RNAi Consulting Services: technology delevopment & evaluation